Ninlaro Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Ixazomib

Indications/Uses

In combination w/ lenalidomide & dexamethasone for adult patients w/ multiple myeloma who have received at least 1 prior therapy.

Dosage/Direction for Use

Starting dose: 4 mg wkly on days 1, 8 & 15 in combination w/ lenalidomide 25 mg daily on days 1-21 & dexamethasone 40 mg on days 1, 8, 15 & 22 of a 28-day treatment cycle. Moderate (total bilirubin >1.5-3x ULN) or severe (total bilirubin>3x ULN) hepatic impairment, severe renal impairment (CrCl <30 mL/min) or ESRD requiring dialysis Reduce starting dose to 3 mg.

Administration

Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after food. Swallow whole w/ water, do not crush/chew/open.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01XG03 - ixazomib ; Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Ninlaro cap 2.3 mg

Packing/Price

1's

Form

Ninlaro cap 3 mg

Packing/Price

3's

Form

Ninlaro cap 4 mg

Packing/Price

3's

Ninlaro

ixazomib

Manufacturer:

Haupt Pharma Amareg